E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有表位，能诱导机体产生体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从宿主撤离，宿主仍能保持对存在于耐受上的免疫表位的特异免疫耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有中和性抗原表位，能诱导机体产生中和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受，将免疫抑制剂从宿主撤离，宿主仍能保持对存在于耐受原上的免疫原性表位的特异性免疫耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有中和性抗原表位，能诱导生中和性抗。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从宿主撤离，宿主仍能保持对存在于耐受原上的免疫原性表位的特异性免疫耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有中和性抗表位，能诱导机体产生中和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将抑制剂从宿主撤离，宿主仍能保持对存在于耐受上的性表位的特异性耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括的E2蛋白含有中和性抗原表位，能诱导机体产生中和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从宿主撤离，宿主仍能保持对存在于耐受原上的免疫原性表位的特异性免疫耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2含有中原表位，能诱导机体产生中体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从宿主撤离，宿主仍能保持对存在于耐受原上的免疫原表位的特异免疫耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有中和性表，诱导机体产生中和性体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从宿撤离，宿保持对存在于耐受上的免疫性表的特异性免疫耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有中和性抗表位，能诱导机体产生中和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐方案后，将免疫抑制剂从宿主撤离，宿主仍能保持对存在于耐的免疫性表位的特异性免疫耐。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有和性抗原表位，能诱导机体和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从宿主撤离，宿主仍能保持对存在于耐受原上的免疫原性表位的特异性免疫耐受。